Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways

Abstract

Ovarian cancer remains the most lethal gynecologic malignancy with late detection and acquired chemoresistance. Advanced understanding of the pathophysiology and novel treatment strategies are urgently required. A growing body of proteomic investigations suggest that phosphorylation has a pivotal role in the regulation of ovarian cancer associated signaling pathways. Matrine has been extensively studied for its potent anti-tumor activities. However, its effect on ovarian cancer cells and underlying molecular mechanisms remain unclear. Herein we showed that matrine treatment inhibited the development and progression of ovarian cancer cells by regulating proliferation, apoptosis, autophagy, invasion and angiogenesis. Matrine treatment retarded the cancer associated signaling transduction by decreasing the phosphorylation levels of ERK1/2, MEK1/2, PI3K, Akt, mTOR, FAK, RhoA, VEGFR2, and Tie2 in vitro and in vivo. Moreover, matrine showed excellent antitumor effect on chemoresistant ovarian cancer cells. No obvious toxic side effects were observed in matrine-administrated mice. As the natural agent, matrine has the potential to be the targeting drug against ovarian cancer cells with the advantages of overcoming the chemotherapy resistance and decreasing the toxic side effects.

A novel multi-scale bioinformatics strategy for identifying the molecular mechanism by insighting into ceRNA network integrating WGCNA and meta-analysis: compound kushen injection for treating gastric carcinoma as a proof

“…We proposed that CKI plays a therapeutic role in the treatment of GC that is mediated by PI3K-AKT pathway, and it has been experimentally con rmed earlier. Previous studies have con rmed that the active ingredients of matrine, oxymatrine and sophoridine in CKI can treat various tumors by inhibiting the PI3K-AKT signaling pathway [70][71][72]. Peng etal [73] found that matrine can inhibit the proliferation and metastasis of gastric cancer cell SGC7901 through PI3K/Akt pathway.…”

Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma

“…For wound healing assays, detailed procedures could follow previous study 35 . Images were taken with a digital camera at different time points under Inverted Microscope (Mshot).…”

Combination of Chinese and western medicine to prevent and reverse resistance of cancer cells to anticancer drugs

“…此时, 若采用简单的更换化疗药物, 或者联合化 [8,9] . 近年来的研究表明, 中药在增强 抗肿瘤药物敏感性和克服肿瘤耐药方面显示出独特的 优势 [10,11] , 为中西结合防治肿瘤耐药提供了新的途径. , 外加药物对其进行的淘汰"选择", 最终导 致肿瘤耐药的发生 [13~15] ; 肿瘤细胞膜转运体蛋白引起 的药物外排增加, 如依赖ATP的药物外排泵(P-gp、 MRP1、BCRP等)可显著降低药物的摄取 [16,17] ; 药物代 谢酶的活性改变, 如细胞色素P450的活性增强 [18] 、谷 胱甘肽S-转移酶π(GSTπ)的活化 [19] 等; DNA损伤修复系 统的激活 [20] ; 肿瘤微环境的变化, 如低氧、内质网应 激、酸性微环境、炎症因子释放等 [21~23] ; 基因突变或 信号通路异常, 如PTEN丢失, C-Met扩增, Notch、…”